38 Publications Available
December 17, 2015

Scientists studied the DNA variant in the LMO1 gene which leads to neuroblastoma development.

December 04, 2015
Nature Communications

Researchers discovered mutations in the MLLT1 gene in Wilms tumor that might help explain Wilms tumor development.

August 01, 2015
Nature Genetics

Whole-genome sequencing showed high frequency of mutations that were predicted to activate the RAS-MAPK pathway in relapse neuroblastoma samples as well as in neuroblastoma cell lines.

June 30, 2015

The authors analyzed a discovery set of 13 CCSKs for changes in chromosome copy number, mutations, rearrangements, global gene expression and global DNA methylation.The study reported significant hypermethylation of TCF21 and/or decreased TARID expression in the cases of most CCSKs.

March 19, 2015
Nature Communcations

Researchers used deep whole-exome sequencing to describe the clonal architecture and evolution of 20 pediatric B-acute lymplobastic leukaemias from diagnosis to relapse.

February 09, 2015
Cancer Cell

The study reported that the most common single-nucleotide substitution/deletion mutations in favorable histology Wilms tumors occur within SIX1/2, and microRNA processing genes DGCR8 and DROSHA. SIX and miRNAPG mutations were reported to be associated with RAS activation.

September 11, 2014
The New England Journal of Medicine

Genomic profiling and analysis of patients with precursor B-cell ALL and those with Ph-like ALL showed that the genomic alterations that characterized Ph-like ALL might be amenable to inhibition with tyrosine kinase inhibitors. 

March 01, 2013
Nature Genetics

TARGET investigators used whole-exome, genome and transcriptome sequencing to determine the spectrum of somatic mutation in high-risk neuroblastoma.

January 17, 2013

Sequencing the tyrosine kinome and downstream signaling genes in high-risk pediatric ALL cases showed no somatic mutations aside from JAK mutations and 1 FLT3 mutation.

December 08, 2012

The study reported that alterations of the lymphoid transcription factor gene IKZF1 (IKAROS) are associated with a high risk of treatment failure in B-ALL and approximately 20% of B-ALL cases have genetic alterations that activate kinase signaling.